





Supplementary Figure 1: Impact of the gametocytemia in *Ookluc* conversion.




Supplementary Figure 2: *Ookluc* is compatible with HTS.



Supplementary Figure 3: Multidimensional scatterplot of *P. berghei* *Ookluc* activity compared to other datasets



Supplementary Figure 4: The most potent compounds do not inhibit nLuc activity in asexual stages of *P. falciparum* and specifically block ookinte formation in *P. berghei* conversion



1 **Supplementary figure legends**

2

3 **Supplementary Figure 1. Impact of the gametocytemia in *Ookluc* conversion.**

4 nLuc activity, expressed as mean \pm SD of Relative Light Units (RLU), after 24 hr of
5 conversion assay with *Ookluc* from mouse donors with different gametocytemia.
6 Results are representative of 3 independent experiments.

7

8 **Supplementary Figure 2. *Ookluc* is compatible with HTS. a.** Distribution of nLuc

9 activity in a semi-HT conversion assay using a 96-well plate. Each bar represents the
10 nLuc activity, expressed as Relative Light Units (RLU), in one well after 24 hours'
11 conversion assay. The horizontal line represents the mean (μ) and the dashed lines
12 represent \pm two standard deviations (2σ). The calculated Z-factor is shown. **b.**
13 Conversion assays were set using different volumes of blood, medium and
14 lysis/substrate, and nLuc activities in time zero (black bars) or after 24 hours (grey
15 bars) are represented as Relative Light Units (RLU) for each condition.

16

17 **Supplementary Figure 3. Multidimensional scatterplot of *Plasmodium berghei***

18 ***Ookluc* activity compared to other datasets.** Comparative activity of the MMV
19 Pathogen Box malarial specific compounds screened previously within the MMV
20 Malaria Box. Shown is the percent inhibition of the select compounds utilizing the
21 *Ookluc* assay screened at a single 10 μ M concentration. Also shown is the percent
22 inhibitory activity, again at a single 10 μ M concentration, against *P. falciparum* NF54
23 stage V gametocytes. Color indication reflects the IC50 against *P. falciparum* 3D7
24 asexual stage parasites with red representing higher potency (0.03 μ M) and blue
25 representing lower potency compound activity (2.10 μ M). Size denotes activity in a *P.*
26 *berghei* sporozoite liver stage assay (% inhibition at 10 μ M single concentration) with
27 the largest size representing 100% inhibition and the smallest representing no
28 detectable inhibition against the liver stage.

29

30 **Supplementary Figure 4. The most potent compounds do not inhibit nLuc**
31 **activity in asexual stages of *P. falciparum* and specifically block ookinete**
32 **formation in *P. berghei* conversion. a.** Samples of a culture of *Pf*-nLuc with 1%

33 parasitemia were incubated with the indicated compounds at a single 10 μ M
34 concentration, in triplicates, for 90 min prior to determination of nLuc activity,
35 expressed as mean + SD of Relative Light Units (RLU). **b.** Ookinete counts (mean +
36 SD) after 24 hr conversion assays of *P. berghei* in the presence of 1 μ M of the indicated
37 compounds. Results are representative of 2 independent experiments.
38